Commentary

Video

Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer

Fact checked by:

Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.

Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, discusses findings from an analysis of ESR1 variant allele frequencies (VAFs) in patients with estrogen receptor (ER)–positive, HER2-negative, advanced or metastatic ESR1-mutated breast cancer who received elacestrant (Orserdu) or standard of care (SOC) in the phase 3 EMERALD trial (NCT03778931).

Related Videos
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
John M. Burke, MD
Eunice S. Wang, MD
Rachel E. Rau, MD
Wade T. Iams, MD
Andrew Kuykendall, MD
Timothy S. Fenske, MD, MS
Dasom (Caroline) Lee, MD
Christina Poh, MD